
Please try another search
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Name | Age | Since | Title |
---|---|---|---|
Donald S. Fong | - | 2020 | Member of Scientific Advisory Board |
Bart Filius | 51 | 2019 | Independent Supervisory Board Member |
James S. Shannon | 65 | 2016 | Independent Member of Supervisory Board & Chairman of Scientific Advisory Board |
Domenico Valerio | 66 | 2014 | Founder & Independent Chairman of Supervisory Board |
Arthur A. Levin | 69 | - | Member of Scientific Advisory Board |
Alison F. Lawton | 62 | 2014 | Independent Member of Supervisory Board |
Theresa Marie Heggie | 63 | 2021 | Supervisory Board Member |
Phillip D. Zamore | - | 2017 | Member of Scientific Advisory Board |
Peter A. Beal | - | 2018 | Member Scientific Advisory Board |
Yi-Tao Yu | - | 2018 | Member of Scientific Advisory Board |
Martin A. Maier | - | 2020 | Member of Scientific Advisory Board |
Begona Carreno | - | 2023 | Supervisory Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review